{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:47:36Z","timestamp":1792802856752,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82101916"],"award-info":[{"award-number":["82101916"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China","award":["LHDMZ22H300005"],"award-info":[{"award-number":["LHDMZ22H300005"]}]},{"name":"Major project of Science and Technology Program of Jinhua, China","award":["2022-3-039"],"award-info":[{"award-number":["2022-3-039"]}]},{"DOI":"10.13039\/100007015","name":"the University of Wisconsin \u2013 Madison","doi-asserted-by":"crossref","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["T32 CA009206"],"award-info":[{"award-number":["T32 CA009206"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lung cancer has been the leading cause of cancer-related deaths worldwide for decades. Despite the increasing understanding of the underlying disease mechanisms, the prognosis still remains poor for many patients. Novel adjuvant therapies have emerged as a promising treatment method to augment conventional methods and boost the therapeutic effects of primary therapies. Adjuvant therapy based on nanomedicine has gained considerable interest for supporting and enhancing traditional therapies, such as chemotherapy, immunotherapy, and radiotherapy, due to the tunable physicochemical features and ease of synthetic design of nanomaterials. In addition, nanomedicine can provide protective effects against other therapies by reducing adverse side effects through precise disease targeting. Therefore, nanomedicine-based adjuvant therapies have been extensively employed in a wide range of preclinical and clinical cancer treatments to overcome the drawbacks of conventional therapies. In this review, we mainly discuss the recent advances in adjuvant nanomedicine for lung cancer treatment and highlight their functions in improving the therapeutic outcome of other therapies, which may inspire new ideas for advanced lung cancer therapies and stimulate research efforts around this topic.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s12951-023-01958-4","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T12:01:48Z","timestamp":1688644908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Nanomedicine-based adjuvant therapy: a promising solution for lung cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Yiming","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"1958_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1958_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1958_CR3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJMra0802714","volume":"359","author":"RS Herbst","year":"2008","unstructured":"Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367\u201380.","journal-title":"N Engl J Med"},{"key":"1958_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446\u201354.","journal-title":"Nature"},{"key":"1958_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40:611\u201325.","journal-title":"J Clin Oncol"},{"key":"1958_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","volume":"12","author":"S Yang","year":"2019","unstructured":"Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12:47.","journal-title":"J Hematol Oncol"},{"key":"1958_CR7","doi-asserted-by":"publisher","first-page":"101887","DOI":"10.1016\/j.ctrv.2019.08.003","volume":"79","author":"F Gelsomino","year":"2019","unstructured":"Gelsomino F, Lamberti G, Parisi C, et al. The evolving landscape of immunotherapy in small-cell lung cancer: a focus on predictive biomarkers. Cancer Treat Rev. 2019;79:101887.","journal-title":"Cancer Treat Rev"},{"key":"1958_CR8","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.2147\/IJN.S378074","volume":"17","author":"M Dessale","year":"2022","unstructured":"Dessale M, Mengistu G, Mengist HM, Nanotechnology. A Promising Approach for Cancer diagnosis, therapeutics and theragnosis. Int J Nanomed. 2022;17:3735\u201349.","journal-title":"Int J Nanomed"},{"key":"1958_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20\u201337.","journal-title":"Nat Rev Cancer"},{"key":"1958_CR10","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.7150\/thno.49577","volume":"10","author":"Y Shi","year":"2020","unstructured":"Shi Y, van der Meel R, Chen X, et al. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10:7921\u20134.","journal-title":"Theranostics"},{"key":"1958_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drudis.2019.09.017","volume":"25","author":"M Norouzi","year":"2020","unstructured":"Norouzi M, Amerian M, Amerian M, et al. Clinical applications of nanomedicine in cancer therapy. Drug Discovery Today. 2020;25:107\u201325.","journal-title":"Drug Discovery Today"},{"key":"1958_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.pulmoe.2020.02.005","volume":"26","author":"R Pirker","year":"2020","unstructured":"Pirker R. Conquering lung cancer: current status and prospects for the future. Pulmonology. 2020;26:283\u201390.","journal-title":"Pulmonology"},{"key":"1958_CR13","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","unstructured":"NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561\u201371.","journal-title":"Lancet"},{"key":"1958_CR14","doi-asserted-by":"publisher","first-page":"n2363","DOI":"10.1136\/bmj.n2363","volume":"375","author":"M Miller","year":"2021","unstructured":"Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ. 2021;375:n2363.","journal-title":"BMJ"},{"key":"1958_CR15","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1007\/s11547-012-0849-z","volume":"117","author":"G Carrafiello","year":"2012","unstructured":"Carrafiello G, Mangini M, Fontana F, et al. Radiofrequency ablation for single lung tumours not suitable for surgery: seven years\u2019 experience. Radiol Med. 2012;117:1320\u201332.","journal-title":"Radiol Med"},{"key":"1958_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.chest.2019.04.010","volume":"156","author":"T Kinoshita","year":"2019","unstructured":"Kinoshita T, Effat A, Gregor A, et al. A novel laser fiberscope for simultaneous imaging and phototherapy of Peripheral Lung Cancer. Chest. 2019;156:571\u20138.","journal-title":"Chest"},{"key":"1958_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543\u201350.","journal-title":"Nature"},{"key":"1958_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/cac2.12153","volume":"41","author":"J Kang","year":"2021","unstructured":"Kang J, Zhang C, Zhong WZ. Neoadjuvant immunotherapy for non-small cell lung cancer: state of the art. Cancer Commun (Lond). 2021;41:287\u2013302.","journal-title":"Cancer Commun (Lond)"},{"key":"1958_CR19","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339.","journal-title":"Lancet"},{"key":"1958_CR20","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24:1845\u201351.","journal-title":"Nat Med"},{"key":"1958_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/resp.12789","volume":"21","author":"A Steven","year":"2016","unstructured":"Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016;21:821\u201333.","journal-title":"Respirology"},{"key":"1958_CR22","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1039\/D1BM00879J","volume":"9","author":"C Xian","year":"2021","unstructured":"Xian C, Chen H, Xiong F, et al. Platinum-based chemotherapy via nanocarriers and co-delivery of multiple drugs. Biomater Sci. 2021;9:6023\u201336.","journal-title":"Biomater Sci"},{"key":"1958_CR23","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041\u201353.","journal-title":"Expert Opin Pharmacother"},{"key":"1958_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013;170:365\u201372.","journal-title":"J Control Release"},{"key":"1958_CR25","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jtho.2021.03.027","volume":"16","author":"Y Yoneshima","year":"2021","unstructured":"Yoneshima Y, Morita S, Ando M, et al. Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J Thorac Oncol. 2021;16:1523\u201332.","journal-title":"J Thorac Oncol"},{"key":"1958_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/wnan.1332","volume":"7","author":"S Movassaghian","year":"2015","unstructured":"Movassaghian S, Merkel OM, Torchilin VP. Applications of polymer micelles for imaging and drug delivery. WIREs Nanomed Nanobiotechnol. 2015;7:691\u2013707.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"1958_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.actbio.2020.12.009","volume":"121","author":"M Norouzi","year":"2021","unstructured":"Norouzi M, Hardy P. Clinical applications of nanomedicines in lung cancer treatment. Acta Biomater. 2021;121:134\u201342.","journal-title":"Acta Biomater"},{"key":"1958_CR28","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2147\/IJN.S122859","volume":"12","author":"J Sun","year":"2017","unstructured":"Sun J, Jiang L, Lin Y, et al. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides. Int J Nanomed. 2017;12:1517\u201337.","journal-title":"Int J Nanomed"},{"key":"1958_CR29","doi-asserted-by":"publisher","first-page":"113974","DOI":"10.1016\/j.addr.2021.113974","volume":"178","author":"J Wang","year":"2021","unstructured":"Wang J, Zhu M, Nie G. Biomembrane-based nanostructures for cancer targeting and therapy: from synthetic liposomes to natural biomembranes and membrane-vesicles. Adv Drug Deliv Rev. 2021;178:113974.","journal-title":"Adv Drug Deliv Rev"},{"key":"1958_CR30","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1021\/acs.bioconjchem.7b00428","volume":"28","author":"L Gao","year":"2017","unstructured":"Gao L, Wang H, Nan L, et al. Erythrocyte membrane-wrapped pH sensitive polymeric nanoparticles for non-small cell lung cancer therapy. Bioconjug Chem. 2017;28:2591\u20138.","journal-title":"Bioconjug Chem"},{"key":"1958_CR31","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.nano.2017.03.001","volume":"13","author":"AK Agrawal","year":"2017","unstructured":"Agrawal AK, Aqil F, Jeyabalan J, et al. Milk-derived exosomes for oral delivery of paclitaxel. Nanomedicine. 2017;13:1627\u201336.","journal-title":"Nanomedicine"},{"key":"1958_CR32","doi-asserted-by":"publisher","first-page":"1904278","DOI":"10.1002\/adma.201904278","volume":"31","author":"J Jiang","year":"2019","unstructured":"Jiang J, Shen N, Ci T, et al. Combretastatin A4 nanodrug-induced MMP9 amplification boosts tumor-selective release of doxorubicin prodrug. Adv Mater. 2019;31:1904278.","journal-title":"Adv Mater"},{"key":"1958_CR33","doi-asserted-by":"publisher","first-page":"111249","DOI":"10.1016\/j.biopha.2021.111249","volume":"136","author":"B Wang","year":"2021","unstructured":"Wang B, Hu W, Yan H, et al. Lung cancer chemotherapy using nanoparticles: enhanced target ability of redox-responsive and pH-sensitive cisplatin prodrug and paclitaxel. Biomed Pharmacother. 2021;136:111249.","journal-title":"Biomed Pharmacother"},{"key":"1958_CR34","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.2147\/DDDT.S172199","volume":"12","author":"J Liu","year":"2018","unstructured":"Liu J, Cheng H, Han L, et al. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles. Drug Des Devel Ther. 2018;12:3199\u2013209.","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 2","key":"1958_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/resp.13870","volume":"25","author":"SK Vinod","year":"2020","unstructured":"Vinod SK, Hau E. Radiotherapy treatment for lung cancer: current status and future directions. Respirology. 2020;25(Suppl 2):61\u201371.","journal-title":"Respirology"},{"key":"1958_CR36","doi-asserted-by":"publisher","first-page":"14026","DOI":"10.1002\/anie.201504536","volume":"54","author":"W Fan","year":"2015","unstructured":"Fan W, Bu W, Zhang Z, et al. X-ray radiation-controlled no-release for on-demand depth-independent hypoxic radiosensitization. Angewandte Chemie. 2015;54:14026\u201330.","journal-title":"Angewandte Chemie"},{"key":"1958_CR37","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3390\/cells9071651","volume":"9","author":"MA Olivares-Urbano","year":"2020","unstructured":"Olivares-Urbano MA, Gri\u00f1\u00e1n-Lis\u00f3n C, Marchal JA, et al. CSC radioresistance: a therapeutic challenge to improve radiotherapy effectiveness in cancer. Cells. 2020;9:1651.","journal-title":"Cells"},{"key":"1958_CR38","doi-asserted-by":"publisher","first-page":"1700996","DOI":"10.1002\/adma.201700996","volume":"29","author":"G Song","year":"2017","unstructured":"Song G, Cheng L, Chao Y, et al. Emerging nanotechnology and advanced materials for cancer radiation therapy. Adv Mater. 2017;29:1700996.","journal-title":"Adv Mater"},{"key":"1958_CR39","doi-asserted-by":"publisher","first-page":"9407","DOI":"10.2147\/IJN.S272902","volume":"15","author":"Y Chen","year":"2020","unstructured":"Chen Y, Yang J, Fu S, et al. Gold nanoparticles as radiosensitizers in cancer radiotherapy. Int J Nanomed. 2020;15:9407\u201330.","journal-title":"Int J Nanomed"},{"key":"1958_CR40","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/metabo12100943","volume":"12","author":"R Zhou","year":"2022","unstructured":"Zhou R, Zhao D, Beeraka NM, et al. Novel implications of nanoparticle-enhanced radiotherapy and brachytherapy: Z-effect and tumor hypoxia. Metabolites. 2022;12:943.","journal-title":"Metabolites"},{"key":"1958_CR41","doi-asserted-by":"publisher","first-page":"101210","DOI":"10.1016\/j.tranon.2021.101210","volume":"14","author":"M Zhuang","year":"2021","unstructured":"Zhuang M, Jiang S, Gu A, et al. Radiosensitizing effect of gold nanoparticle loaded with small interfering RNA-SP1 on lung cancer: AuNPs-si-SP1 regulates GZMB for radiosensitivity. Translational Oncol. 2021;14:101210.","journal-title":"Translational Oncol"},{"key":"1958_CR42","doi-asserted-by":"publisher","first-page":"2200143","DOI":"10.1002\/adhm.202200143","volume":"11","author":"J Xiao","year":"2022","unstructured":"Xiao J, Zeng L, Ding S, et al. Tumor-tropic adipose-derived mesenchymal stromal cell mediated Bi2Se3 nano-radiosensitizers delivery for targeted radiotherapy of non-small cell lung cancer. Adv Healthc Mater. 2022;11:2200143.","journal-title":"Adv Healthc Mater"},{"key":"1958_CR43","doi-asserted-by":"publisher","first-page":"598997","DOI":"10.3389\/fbioe.2020.598997","volume":"8","author":"J Tian","year":"2020","unstructured":"Tian J, Wei X, Zhang W, et al. Effects of selenium nanoparticles combined with radiotherapy on lung cancer cells. Front Bioeng Biotechnol. 2020;8:598997.","journal-title":"Front Bioeng Biotechnol"},{"key":"1958_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2014.12.018","volume":"201","author":"IA Khawar","year":"2015","unstructured":"Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release. 2015;201:78\u201389.","journal-title":"J Control Release"},{"key":"1958_CR45","doi-asserted-by":"publisher","first-page":"7667","DOI":"10.1039\/D1BM01127H","volume":"9","author":"AVVV Ravi Kiran","year":"2021","unstructured":"Ravi Kiran AVVV, Kusuma Kumari G, Krishnamurthy PT, et al. Tumor microenvironment and nanotherapeutics: intruding the tumor fort. Biomaterials Sci. 2021;9:7667\u2013704.","journal-title":"Biomaterials Sci"},{"key":"1958_CR46","doi-asserted-by":"publisher","first-page":"2003584","DOI":"10.1002\/advs.202003584","volume":"7","author":"S Clement","year":"2020","unstructured":"Clement S, Campbell JM, Deng W, et al. Mechanisms for tuning engineered nanomaterials to enhance radiation therapy of cancer. Adv Sci. 2020;7:2003584.","journal-title":"Adv Sci"},{"key":"1958_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.actbio.2021.02.001","volume":"124","author":"M Zhang","year":"2021","unstructured":"Zhang M, Hagan CT, t, Foley H, et al. Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models. Acta Biomater. 2021;124:327\u201335.","journal-title":"Acta Biomater"},{"key":"1958_CR48","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1080\/10717544.2022.2036871","volume":"29","author":"J Wang","year":"2022","unstructured":"Wang J, Zhang Y, Zhang G, et al. Radiotherapy-induced enrichment of EGF-modified doxorubicin nanoparticles enhances the therapeutic outcome of lung cancer. Drug Deliv. 2022;29:588\u201399.","journal-title":"Drug Deliv"},{"key":"1958_CR49","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of Immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069\u201386.","journal-title":"Cancer Discov"},{"key":"1958_CR50","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","volume":"154","author":"K Suresh","year":"2018","unstructured":"Suresh K, Naidoo J, Lin CT, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest. 2018;154:1416\u201323.","journal-title":"Chest"},{"key":"1958_CR51","doi-asserted-by":"publisher","first-page":"989461","DOI":"10.3389\/fphar.2022.989461","volume":"13","author":"T Yang","year":"2022","unstructured":"Yang T, Xiong Y, Zeng Y, et al. Current status of immunotherapy for non-small cell lung cancer. Front Pharmacol. 2022;13:989461.","journal-title":"Front Pharmacol"},{"key":"1958_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20:25\u201339.","journal-title":"Nat Rev Immunol"},{"key":"1958_CR53","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","volume":"19","author":"MS Goldberg","year":"2019","unstructured":"Goldberg MS. Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer. 2019;19:587\u2013602.","journal-title":"Nat Rev Cancer"},{"key":"1958_CR54","doi-asserted-by":"publisher","first-page":"8382","DOI":"10.7150\/thno.45391","volume":"10","author":"Q Yang","year":"2020","unstructured":"Yang Q, Shi G, Chen X, et al. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 immunotherapy. Theranostics. 2020;10:8382\u201399.","journal-title":"Theranostics"},{"key":"1958_CR55","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1039\/D1BM00112D","volume":"9","author":"Y Wang","year":"2021","unstructured":"Wang Y, Shen N, Wang Y, et al. Cisplatin nanoparticles boost abscopal effect of radiation plus anti-PD1 therapy. Biomater Sci. 2021;9:3019\u201327.","journal-title":"Biomater Sci"},{"key":"1958_CR56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12951-021-01017-w","volume":"19","author":"HZ Xu","year":"2021","unstructured":"Xu HZ, Li TF, Wang C, et al. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells. J Nanobiotechnol. 2021;19:268.","journal-title":"J Nanobiotechnol"},{"key":"1958_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.actbio.2019.08.046","volume":"99","author":"B Liu","year":"2019","unstructured":"Liu B, Cao W, Qiao G, et al. Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer. Acta Biomater. 2019;99:307\u201319.","journal-title":"Acta Biomater"},{"key":"1958_CR58","doi-asserted-by":"publisher","first-page":"e2200938","DOI":"10.1002\/adhm.202200938","volume":"11","author":"L Zhou","year":"2022","unstructured":"Zhou L, Liang H, Ge Y, et al. Precisely targeted nano-controller of PD-L1 level for non-small cell lung cancer spinal metastasis immunotherapy. Adv Healthc Mater. 2022;11:e2200938.","journal-title":"Adv Healthc Mater"},{"key":"1958_CR59","doi-asserted-by":"publisher","first-page":"8035","DOI":"10.3390\/ijms22158035","volume":"22","author":"CG Kim","year":"2021","unstructured":"Kim CG, Sang YB, Lee JH, et al. Combining cancer vaccines with immunotherapy: establishing a new immunological approach. Int J Mol Sci. 2021;22:8035.","journal-title":"Int J Mol Sci"},{"key":"1958_CR60","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1021\/acs.accounts.0c00456","volume":"53","author":"ME Aikins","year":"2020","unstructured":"Aikins ME, Xu C, Moon JJ. Engineered nanoparticles for cancer vaccination and immunotherapy. Acc Chem Res. 2020;53:2094\u2013105.","journal-title":"Acc Chem Res"},{"key":"1958_CR61","doi-asserted-by":"publisher","first-page":"7072","DOI":"10.7150\/thno.57803","volume":"11","author":"CH Hsieh","year":"2021","unstructured":"Hsieh CH, Hsieh HC, Shih FS, et al. An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment. Theranostics. 2021;11:7072\u201391.","journal-title":"Theranostics"},{"key":"1958_CR62","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.nano.2021.102415","volume":"37","author":"J Koh","year":"2021","unstructured":"Koh J, Kim S, Lee SN, et al. Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7\/8 agonist in lung cancer model. Nanomedicine. 2021;37:102415.","journal-title":"Nanomedicine"},{"key":"1958_CR63","first-page":"10369","volume":"129","author":"H Ye","year":"2020","unstructured":"Ye H, He X, Feng X. Developing neobavaisoflavone nanoemulsion suppresses lung cancer progression by regulating tumor microenvironment. Biomedicine. 2020;129:10369.","journal-title":"Biomedicine"},{"key":"1958_CR64","doi-asserted-by":"publisher","first-page":"119599","DOI":"10.1016\/j.biomaterials.2019.119599","volume":"230","author":"HT Duong","year":"2020","unstructured":"Duong HT, Thambi T, Yin T. Degradation-regulated architecture of injectable smart hydrogels enhances humoral immune response and potentiates antitumor activity in human lung carcinoma. Biomaterials. 2020;230:119599.","journal-title":"Biomaterials"},{"key":"1958_CR65","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jconrel.2017.03.028","volume":"259","author":"E Oh","year":"2017","unstructured":"Oh E, Oh JE, Hong J, et al. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy. J Control Release. 2017;259:115\u201327.","journal-title":"J Control Release"},{"key":"1958_CR66","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12032-020-01361-1","volume":"37","author":"SG Picchi","year":"2020","unstructured":"Picchi SG, Lassandro G, Bianco A, et al. RFA ofprimary and metastatic lung tumors: long-term results. Med Oncol. 2020;37:35.","journal-title":"Med Oncol"},{"key":"1958_CR67","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijsu.2018.03.034","volume":"53","author":"BY Huang","year":"2018","unstructured":"Huang BY, Li XM, Song XY, et al. Long-term results of CT-guided percutaneous radiofrequency ablation of inoperable patients with stage Ia non-small cell lung cancer: a retrospective cohort study. Int J Surg. 2018;53:143\u201350.","journal-title":"Int J Surg"},{"key":"1958_CR68","doi-asserted-by":"publisher","first-page":"e199702","DOI":"10.1001\/jamanetworkopen.2019.9702","volume":"2","author":"J Uhlig","year":"2019","unstructured":"Uhlig J, Case MD, Blasberg JD, et al. Comparison of survival rates after a combination of local treatment and systemic therapy vs systemic therapy alone for treatment of stage IV non-small cell lung cancer. JAMA Netw open. 2019;2:e199702.","journal-title":"JAMA Netw open"},{"key":"1958_CR69","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41423-018-0184-y","volume":"16","author":"A Xu","year":"2019","unstructured":"Xu A, Zhang L, Yuan J, et al. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis. Cell Mol Immunol. 2019;16:820\u201332.","journal-title":"Cell Mol Immunol"},{"key":"1958_CR70","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41392-021-00745-7","volume":"6","author":"M Li","year":"2021","unstructured":"Li M, Hao B, Zhang M, et al. Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development. Signal Transduct Target Ther. 2021;6:330.","journal-title":"Signal Transduct Target Ther"},{"key":"1958_CR71","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1038\/s41467-021-24604-9","volume":"12","author":"Z Yang","year":"2021","unstructured":"Yang Z, Zhu Y, Dong Z, et al. Tumor-killing nanoreactors fueled by tumor debris can enhance radiofrequency ablation therapy and boost antitumor immune responses. Nat Commun. 2021;12:4299.","journal-title":"Nat Commun"},{"key":"1958_CR72","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40580-022-00328-4","volume":"9","author":"SB Aboeleneen","year":"2022","unstructured":"Aboeleneen SB, Scully MA, Harris JC, et al. Membrane-wrapped nanoparticles for photothermal cancer therapy. Nano Converg. 2022;9:37.","journal-title":"Nano Converg"},{"key":"1958_CR73","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.biopha.2018.07.049","volume":"106","author":"S Kwiatkowski","year":"2018","unstructured":"Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy\u2014mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098\u2013107.","journal-title":"Biomed Pharmacother"},{"key":"1958_CR74","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1039\/C7BM01210A","volume":"6","author":"H Zhu","year":"2018","unstructured":"Zhu H, Cheng P, Chen P, et al. Recent progress in the development of near-infrared organic photothermal and photodynamic nanotherapeutics. Biomater Sci. 2018;6:746\u201365.","journal-title":"Biomater Sci"},{"key":"1958_CR75","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1039\/C8CS00618K","volume":"48","author":"Y Liu","year":"2019","unstructured":"Liu Y, Bhattarai P, Dai Z, et al. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev. 2019;48:2053\u2013108.","journal-title":"Chem Soc Rev"},{"key":"1958_CR76","doi-asserted-by":"publisher","first-page":"1804105","DOI":"10.1002\/smll.201804105","volume":"15","author":"X Zhen","year":"2019","unstructured":"Zhen X, Cheng P, Pu K. Recent advances in cell membrane\u2013camouflaged nanoparticles for Cancer Phototherapy. Small. 2019;15:1804105.","journal-title":"Small"},{"key":"1958_CR77","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jconrel.2019.12.013","volume":"318","author":"L Qin","year":"2020","unstructured":"Qin L, Jiang S, He H, et al. Functional black phosphorus nanosheets for cancer therapy. J Control Release. 2020;318:50\u201366.","journal-title":"J Control Release"},{"key":"1958_CR78","doi-asserted-by":"publisher","first-page":"121425","DOI":"10.1016\/j.biomaterials.2022.121425","volume":"282","author":"R Guo","year":"2022","unstructured":"Guo R, Wang S, Zhao L, et al. Engineered nanomaterials for synergistic photo-immunotherapy. Biomaterials. 2022;282:121425.","journal-title":"Biomaterials"},{"key":"1958_CR79","doi-asserted-by":"publisher","first-page":"7176","DOI":"10.1039\/C9TB01874C","volume":"7","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Wang R, Li W, et al. Construction of DOX\/APC co-loaded BiOI@CuS NPs for safe and highly effective CT imaging and chemo-photothermal therapy of lung cancer. J Mater Chem B. 2019;7:7176\u201383.","journal-title":"J Mater Chem B"},{"key":"1958_CR80","doi-asserted-by":"publisher","first-page":"e1904397","DOI":"10.1002\/smll.201904397","volume":"15","author":"Y Lai","year":"2019","unstructured":"Lai Y, Xu Z, Hu X, et al. Peptide nanotube-templated biomineralization of Cu(2-)(x) S nanoparticles for combination treatment of metastatic tumor. Small. 2019;15:e1904397.","journal-title":"Small"},{"key":"1958_CR81","doi-asserted-by":"publisher","first-page":"19939","DOI":"10.1039\/D0NR05953F","volume":"12","author":"Q Liu","year":"2020","unstructured":"Liu Q, Fan T, Zheng Y, et al. Immunogenic exosome-encapsulated black phosphorus nanoparticles as an effective anticancer photo-nanovaccine. Nanoscale. 2020;12:19939\u201352.","journal-title":"Nanoscale"},{"key":"1958_CR82","doi-asserted-by":"publisher","first-page":"121808","DOI":"10.1016\/j.biomaterials.2022.121808","volume":"289","author":"D Huang","year":"2022","unstructured":"Huang D, Wu T, Lan S, et al. In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors. Biomaterials. 2022;289:121808.","journal-title":"Biomaterials"},{"key":"1958_CR83","doi-asserted-by":"publisher","first-page":"10099","DOI":"10.1021\/acsnano.5b03677","volume":"9","author":"M Zhao","year":"2015","unstructured":"Zhao M, Li H, Bu X, et al. Quantitative proteomic analysis of Cellular Resistance to the nanoparticle abraxane. ACS Nano. 2015;9:10099\u2013112.","journal-title":"ACS Nano"},{"key":"1958_CR84","doi-asserted-by":"publisher","first-page":"107438","DOI":"10.1016\/j.pharmthera.2019.107438","volume":"206","author":"WJ Liu","year":"2020","unstructured":"Liu WJ, Du Y, Wen R, et al. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol Ther. 2020;206:107438.","journal-title":"Pharmacol Ther"},{"key":"1958_CR85","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s12272-021-01312-y","volume":"44","author":"HY Min","year":"2021","unstructured":"Min HY, Lee HY. Mechanisms of resistance to chemotherapy in non-small cell lung cancer. Arch Pharm Res. 2021;44:146\u201364.","journal-title":"Arch Pharm Res"},{"key":"1958_CR86","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1016\/j.biomaterials.2013.01.055","volume":"34","author":"N Li","year":"2013","unstructured":"Li N, Zhang CX, Wang XX, et al. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways. Biomaterials. 2013;34:3366\u201380.","journal-title":"Biomaterials"},{"key":"1958_CR87","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.biomaterials.2015.02.004","volume":"52","author":"L Jiang","year":"2015","unstructured":"Jiang L, Li L, He X, et al. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. Biomaterials. 2015;52:126\u201339.","journal-title":"Biomaterials"},{"key":"1958_CR88","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41392-020-0115-0","volume":"5","author":"Y Tie","year":"2020","unstructured":"Tie Y, Zheng H, He Z, et al. Targeting folate receptor \u03b2 positive tumor-associated macrophages in lung cancer with a folate-modified liposomal complex. Signal Transduct Target Ther. 2020;5:6.","journal-title":"Signal Transduct Target Ther"},{"key":"1958_CR89","doi-asserted-by":"publisher","first-page":"122540","DOI":"10.1016\/j.cej.2019.122540","volume":"380","author":"X Zhang","year":"2020","unstructured":"Zhang X, He C, Yan R, et al. HIF-1 dependent reversal of cisplatin resistance via anti-oxidative nano selenium for effective cancer therapy. Chem Eng J. 2020;380:122540.","journal-title":"Chem Eng J"},{"key":"1958_CR90","doi-asserted-by":"publisher","first-page":"e2201516","DOI":"10.1002\/adma.202201516","volume":"34","author":"J Huang","year":"2022","unstructured":"Huang J, Zhuang C, Chen J, et al. Targeted drug\/gene\/photodynamic therapy via a stimuli-responsive dendritic-polymer-based nanococktail for treatment of EGFR-TKI-resistant non-small-cell lung cancer. Adv Mater. 2022;34:e2201516.","journal-title":"Adv Mater"},{"key":"1958_CR91","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.7150\/thno.24469","volume":"8","author":"S Li","year":"2018","unstructured":"Li S, Liu Y, Rui Y, et al. Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system. Theranostics. 2018;8:2621\u201333.","journal-title":"Theranostics"},{"key":"1958_CR92","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-022-01320-5","volume":"15","author":"H Tian","year":"2022","unstructured":"Tian H, Zhang T, Qin S, et al. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J Hematol Oncol. 2022;15:132.","journal-title":"J Hematol Oncol"},{"key":"1958_CR93","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jconrel.2020.01.035","volume":"320","author":"AC Marques","year":"2020","unstructured":"Marques AC, Costa PJ, Velho S, et al. Functionalizing nanoparticles with cancer-targeting antibodies: a comparison of strategies. J Control Release. 2020;320:180\u2013200.","journal-title":"J Control Release"},{"key":"1958_CR94","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/10717544.2021.1938757","volume":"28","author":"A Li","year":"2021","unstructured":"Li A, Zhao Y, Li Y, et al. Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles. Drug Deliv. 2021;28:1237\u201355.","journal-title":"Drug Deliv"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01958-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T13:03:58Z","timestamp":1688648638000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01958-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1958"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01958-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"assertion":[{"value":"6 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Weibo Cai declares competing interests with the following corporations: Actithera, Inc., Rad Source Technologies, Inc., Portrai, Inc., rTR Technovation Corporation, and Four Health Global Pharmaceuticals Inc. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}